VSTM2L
V-set and transmembrane domain-containing protein 2-like protein
Also known as: C20orf102, dJ1118M15.2, VTM2L_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96N03
- Gene
- VSTM2L
- Ensembl
- ENSG00000132821
- Chromosome
- 20
- Canonical length
- 204 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted - unknown location
OverviewNCBI Gene
Involved in negative regulation of neuron apoptotic process. Located in cytoplasm and extracellular region. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
204 residues, UniProt reviewed canonical sequence.
>Q96N03|VSTM2L
1 MGAPLAVALG ALHYLALFLQ LGGATRPAGH APWDNHVSGH ALFTETPHDM TARTGEDVEM
61 ACSFRGSGSP SYSLEIQWWY VRSHRDWTDK QAWASNQLKA SQQEDAGKEA TKISVVKVVG
121 SNISHKLRLS RVKPTDEGTY ECRVIDFSDG KARHHKVKAY LRVQPGENSV LHLPEAPPAA
181 PAPPPPKPGK ELRKRSVDQE ACSLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against VSTM2L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.48
- Highest tissue expression
- 98 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 98 nTPM
- hippocampal formation: 92 nTPM
- heart muscle: 79 nTPM
- amygdala: 68 nTPM
- hypothalamus: 54 nTPM
- spleen: 29 nTPM
Single-cell type
- respiratory ciliated cells: 219 nCPM
- salivary duct cells: 120 nCPM
- fallopian tube ciliated cells: 90 nCPM
- other brain neurons: 79 nCPM
- adrenal medulla cells: 75 nCPM
- brain inhibitory neurons: 73 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- hippocampal formation: 222 nTPM
- cerebral cortex: 203 nTPM
- hypothalamus: 136 nTPM
- spinal cord: 121 nTPM
- midbrain: 117 nTPM
- amygdala: 112 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.84
- gnomAD pLI
- 0.25
- gnomAD missense Z
- 0.2
- DepMap mean gene effect
- 0.06
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of VSTM2L in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads VSTM2L as an antibody target. Whether an autoantibody or antibody against VSTM2L could matter depends on whether native VSTM2L is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
VSTM2L is annotated as secreted, so native VSTM2L circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label VSTM2L as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...